Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | FADS1 | O60427 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8204221 | 0.83 | ALOX5 (0.43) | ALOX5OPRM1 | |
| SCHEMBL3479604 | 0.80 | MCHR1 (0.48) | MCHR1NSD2ALOX5DRD2DRD3 | |
| Trifluoroacetic Acid SCHEMBL4252943 | 0.76 | ALOX5 (0.38) | ALOX5OPRM1 | |
| SCHEMBL13030986 | 0.73 | MCHR1 (0.48) | MCHR1OPRM1KCNH2SIGMAR1 | |
| SCHEMBL10263218 | 0.72 | ALOX5 (0.42) | ALOX5OPRM1KCNH2SIGMAR1 | |
| SCHEMBL3479525 | 0.72 | BACE1 (0.49) | MCHR1 | |
| SCHEMBL3479505 | 0.70 | MCHR1 (0.41) | MCHR1NSD2ALOX5DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL2432498 | 0.67 | ALOX5 (0.42) | ALOX5OPRM1 | |
| Hydrochloric Acid SCHEMBL20141027 | 0.67 | DRD2 (0.61) | NSD2ALOX5DRD2DRD3NOTUM | |
| SCHEMBL20158985 | 0.65 | DRD2 (0.63) | NSD2ALOX5DRD2DRD3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | MERCK & CO., INC. (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298342-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease | BACE1, APP, PSEN1 | MCHR1 4417/4885NSD2 3703/4885ALOX5 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.